BioMarin Pharmaceutical's quarterly market cap
declined
from Sep. 2024 ($13,394 Mil) to Dec. 2024 ($12,539 Mil) but then
increased
from Dec. 2024 ($12,539 Mil) to Mar. 2025 ($13,555 Mil).
BioMarin Pharmaceutical's annual market cap
declined
from Dec. 2022 ($19,275 Mil) to Dec. 2023 ($18,185 Mil) and
declined
from Dec. 2023 ($18,185 Mil) to Dec. 2024 ($12,539 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. BioMarin Pharmaceutical's Enterprise Value for Today is $10,105 Mil.
BioMarin Pharmaceutical Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of BioMarin Pharmaceutical's Market Cap
For the Biotechnology subindustry, BioMarin Pharmaceutical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's Market Cap distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
BioMarin Pharmaceutical's Market Cap for the fiscal year that ended in Dec. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioMarin Pharmaceutical (NAS:BMRN) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
BioMarin Pharmaceutical Market Cap Related Terms
Thank you for viewing the detailed overview of BioMarin Pharmaceutical's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your 